Millendo Therapeutics (United States)

Alternate names: Millendo, Millendo Therapeutics, Millendo Therapeutics, Inc.

ROR: 03bkk1w14

OpenAlex ID: I4405271968

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

2017 · Julia K Prague, Rachel E Roberts, et al. · The Lancet · 205

PDF

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action

2018 · Julia K. Prague, Rachel E. Roberts, et al. · Menopause The Journal of The North American Menopause Society · 94

A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma

2020 · David C. Smith, Matthias Kroiss, et al. · Investigational New Drugs · 61

A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia

2020 · Diala El-Maouche, Deborah P Merke, et al. · The Journal of Clinical Endocrinology & Metabolism · 34

ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing’s syndrome

2018 · Daniel K. Langlois, Michele C. Fritz, et al. · BMC Endocrine Disorders · 22

PDF

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

2018 · Naidong Ye, Scott A. Monk, et al. · Clinical Pharmacology in Drug Development · 17

PDF

SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims

2020 · Shawn E McCandless, Marissa Suh, et al. · Journal of the Endocrine Society · 11

PDF

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

2017 · Julia Prague, Rachel Roberts, et al. · Endocrine Abstracts · 4

SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome

2020 · Rania Harisseh, Thomas Delale, et al. · Journal of the Endocrine Society · 3

PDF

Neurokinin 3 Receptor Antagonism Rapidly Improves Vasomotor Symptoms With Sustained Duration of Action

2019 · Julia K. Prague, Rachel E. Roberts, et al. · Obstetrical & Gynecological Survey · 2

US immigration order strikes against biotech

2017 · Jeremy M Levin, Steven H Holtzman, et al. · Nature Biotechnology · 2

Pro22 Cost of Care Analysis for U.s. Patients With Prader-willi Syndrome (pws)

2020 · M.G. Butler, A. Manzardo, et al. · Value in Health · 1

PDF

MON-102 Nonclinical Development of AZP-531 (Livoletide): A Peptide Analog of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome

2019 · Stephane Milano, Soraya Allas, et al. · Journal of the Endocrine Society · 1

SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome

2019 · Soraya Allas, Pharis Mohideen, et al. · Journal of the Endocrine Society · 1

SUN-608 Juvenile Toxicity Study of Livoletide: A Peptide Analogue of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome

2020 · Howard Xu, Andrew Spencer, et al. · Journal of the Endocrine Society

PDF

SUN-595 Comparative Comorbidity Burden Among Patients with Prader-Willi Syndrome: A Population-Level Cohort Study

2020 · Diane E J Stafford, Justin W Li, et al. · Journal of the Endocrine Society

PDF

SUN-597 Healthcare Utilization Patterns Among Commercially Insured Patients with Prader-Willi Syndrome: A Retrospective Analysis of Administrative Claims

2020 · Merlin G Butler, Ann M Manzardo, et al. · Journal of the Endocrine Society

PDF

SUN-357 Trial in Progress: A Multicenter, Dose-titration, Open-Label Phase 2b Study of Nevanimibe Hydrochloride, a Novel ACAT1 Inhibitor, for the Treatment of Classic Congenital Adrenal Hyperplasia

2019 · Vivian Lin, M. Marian Ijzerman, et al. · Journal of the Endocrine Society

Biotech leaders call for free press

2018 · Ron Cohen, Steven Holtzman, et al. · Nature Biotechnology

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: A phase 2, randomised, double-blind, placebo controlled trial

2017 · Julia Prague, Rachel Roberts, et al. · Maturitas

Works count: 20

Citation count: 881